Failure of miltefosine treatment for visceral leishmaniasis in children and men in South-East Asia

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Ostyn, Bart ^a   Hasker, Epco ^a   Dorlo, Thomas P C ^b   Rijal, Suman ^c   Sundar, Shyam ^d   Dujardin, Jean Claude ^a   Boelaert, Marleen ^a  

^a INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^b UTRECHT UNIVERSITY   (Netherlands)

^c B P KOIRALA INSTITUTE OF HEALTH SCIENCES   (Nepal)

^d BANARAS HINDU UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

MILTEFOSINE; ANTIPROTOZOAL AGENT; PHOSPHORYLCHOLINE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; CHILD; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE PREDISPOSITION; DRUG SAFETY; DRUG TREATMENT FAILURE; FEMALE; GENDER BIAS; HUMAN; INDIA; MAJOR CLINICAL STUDY; MALE; NEPAL; OBSERVATIONAL STUDY; ORGAN SIZE; PRACTICE GUIDELINE; PRESCHOOL CHILD; PROSPECTIVE STUDY; RECURRENCE RISK; SCHOOL CHILD; SEX DIFFERENCE; SPLEEN; SYMPTOMATOLOGY; TREATMENT RESPONSE; UNIVERSITY HOSPITAL; VISCERAL LEISHMANIASIS; YOUNG ADULT; AGE; ANALOGS AND DERIVATIVES; DRUG EFFECTS; DRUG SENSITIVITY; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; PARASITOLOGY; PHYSIOLOGY; RECURRENT DISEASE; RISK FACTOR; TREATMENT FAILURE;

ADOLESCENT; ADULT; AGE FACTORS; ANTIPROTOZOAL AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INDIA; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; MALE; NEPAL; PARASITIC SENSITIVITY TESTS; PHOSPHORYLCHOLINE; PRACTICE GUIDELINES AS TOPIC; PROSPECTIVE STUDIES; RECURRENCE; RISK FACTORS; SEX FACTORS; TREATMENT FAILURE;

EID: 84903291820     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0100220     Document Type: Article

References (42)

1. Guerin PJ, Olliaro P, Sundar S, Boelaert M, Croft SL, et al. (2002) Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. Lancet Infect Dis. 2: 494-501. (Pubitemid 34826855)
2. Banjara MR, Hirve S, Siddiqui NA, Kumar N, Kansal S, et al. (2012) Visceral leishmaniasis clinical management in endemic districts of India, Nepal, and Bangladesh. J Trop Med. 2012: 126093. doi:10.1155/2012/126093.
3. Croft SL, Sundar S, Fairlamb AH. (2006) Drug resistance in leishmaniasis. Clin Microbiol Rev. 19: 111-26. (Pubitemid 43157649)
4. Ostyn B, Malaviya P, Hasker E, Uranw S, Singh RP, et al. (2013) Retrospective Quarterly Cohort Monitoring for patients with Visceral Leishmaniasis in the Indian subcontinent: outcomes of a pilot project. Trop Med Int Health. 18: 725-33.
5. Malaviya P, Singh RP, Singh SP, Hasker E, Ostyn B, et al. (2011) Monitoring drug effectiveness in kala azar in Bihar, India: cost and feasibility of periodic random surveys vs. a health service-based reporting system. Trop Med Int Health. 16: 1159-66.
6. Khader A, Farajallah L, Shahin Y, Hababeh M, Abu-Zayed I, et al. (2012) Cohort monitoring of persons with diabetes mellitus in a primary healthcare clinic for Palestine refugees in Jordan. Trop Med Int Health. 17: 1569-1576.
7. Khader A, Farajallah L, Shahin Y, Hababeh M, Abu-Zayed I, et al. (2012) Cohort monitoring of persons with hypertension: an illustrated example from a primary healthcare clinic for Palestine refugees in Jordan. Trop Med Int Health. 17: 1163-70.
8. Rijal S, Ostyn B, Uranw S, Rai K, Bhattarai NR, et al. (2013) Increasing Failure of Miltefosine in the Treatment of Kala-azar in Nepal and the Potential Role of Parasite Drug Resistance, Reinfection, or Noncompliance. Clin Infect Dis. 56: 1530-8.
9. Sundar S, Singh A, Rai M, Prajapati VK, Singh AK, et al. (2012) Efficacy of miltefosine in the treatment of visceral leishmaniasis in India after a decade of use. Clin Infect Dis. 55: 543-50.
10. Prajapati VK, Sharma S, Rai M, Ostyn B, Salotra P, et al. (2013) In vitro susceptibility of Leishmania donovani to Miltefosine in Indian Visceral Leishmaniasis. Am J Trop Med Hyg. 89: 750-4.
11. Sundar S, Thakur BB, Tandon AK, Agrawal NR, Mishra CP, et al. (1994) Clinicoepidemiological study of drug resistance in Indian kala-azar. BMJ. 308: 307. (Pubitemid 24084143)
12. Gorski S, Collin SM, Ritmeijer K, Keus K, Gatluak F, et al. (2010) Visceral leishmaniasis relapse in Southern Sudan (1999-2007): a retrospective study of risk factors and trends. PLoS Negl Trop Dis. 4(6): e705. doi: 10.1371/journal.pntd.0000705.
13. Bhandari V, Kulshrestha A, Deep DK, Stark O, Prajapati VK, et al. (2012) Drug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis. PLoS Negl Trop Dis. 6(5): e1657. doi: 10.1371/journal.pntd.0001657.
14. Uranw S, Ostyn B, Dorlo TP, Hasker E, Dujardin B, et al. (2013) Adherence to miltefosine treatment for visceral leishmaniasis under routine conditions in Nepal. Trop Med Int Health. 18: 179-87.
15. Murray HW. (2005) Prevention of relapse after chemotherapy in a chronic intracellular infection: mechanisms in experimental visceral leishmaniasis. J Immunol. 174: 4916-23.
16. Rai K, Cuypers B, Bhattarai NR, Uranw S, Berg M, et al. (2013) Relapse after treatment with miltefosine for Visceral Leishmaniasis is associated with increased infectivity of the infecting Leishmania donovani strain. MBio. 4 doi:pii: e00611-13.10.1128/mBio.00611-13.
17. Ribeiro V, Cavaco I. (2006) Pharmacogenetics of cytochromes P450 in tropical medicine. Curr Drug Targets. 7: 1709-19. (Pubitemid 44873732)
18. Wijers DJ, Van Joost KS, Janssen JA, Blommers LH. (1969) Differences in resistance against Kala-azar (Kenya strain) between males and females. Trop Geogr Med. 21: 436-442.
19. Sharma MC, Gupta AK, Sharan R, Sinha SP. (1990) The effect of age and sex on incidence of Kala-azar. J Comm Dis. 22: 277-278.
20. Sundar S, Jha TK, Thakur CP, Engel J, Sindermann H, et al. (2002) Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med. 347: 1739-46. (Pubitemid 35375612)
21. Bhattacharya SK, Sinha PK, Sundar S, Thakur CP, Jha TK, et al. (2007) Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis. J Infect Dis. 196: 591-8. (Pubitemid 47206107)
22. Sundar S, Jha TK, Sindermann H, Junge K, Bachmann P, et al. (2003) Oral miltefosine treatment in children with mild to moderate Indian visceral leishmaniasis. Pediatr J Infect Dis. 22: 434-8. (Pubitemid 36578746)
23. Dorlo TP, Balasegaram M, Beijnen JH, de Vries PJ. (2012) Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis. J Antimicrob Chemother. 67: 2576-97. doi: 10.1093/jac/dks275.
24. Dorlo TP, Huitema AD, Beijnen JH, de Vries PJ. (2012) Optimal dosing of miltefosine in children and adults with visceral leishmaniasis. Antimicrob Agents Chemother. 56: 3864-72.
25. Dorlo TP, Rijal S, Ostyn B, de Vries PJ, Singh RP, et al. (2014) Failure of miltefosine in visceral leishmaniasis is associated with low drug exposure. J Infect Dis. doi: 10.1093/infdis/jiu039.
26. Cruz A, Rainey PM, Herwaldt BL, Stagni G, Palacios R, et al. (2007) Pharmacokinetics of antimony in children treated for leishmaniasis with meglumine antimoniate. J Infect Dis. 195: 602-8. (Pubitemid 46214405)
27. Bryceson AD, Chulay JD, Ho M, Were JB, Gachihi G, et al. (1985) Visceral leishmaniasis unresponsive to antimonial drugs. I. Clinical and immunological studies. Trans R Soc Trop Med Hyg 79: 700-4. (Pubitemid 16249111)
28. Klein SL. (2004) Hormonal and immunological mechanisms mediating sex differences in parasite infection. Parasite Immunology 26: 247-264.
29. Zuk M, McKean KA. (1996) Sex differences in parasite infections: patterns and processes. Int J Parasitol. 26: 1009-23. (Pubitemid 27294169)
30. Weigle KA, Santrich C, Martinez F, Valderrama L, Saravia NG. (1993) Epidemiology of cutaneous leishmaniasis in Colombia: a longitudinal study of the natural history, prevalence, and incidence of infection and clinical manifestations. J Infect Dis. 168: 699-708. (Pubitemid 23254291)
31. Shiddo SA, Aden MA, Akuffo HO, Mohamud KA, Herzi AA, et al. (1995) Visceral leishmaniasis in Somalia: prevalence of markers of infection and disease manifestations in a village in an endemic area. Trans R Soc Trop Med Hyg 89: 361-365.
32. Jeronimo SM, Duggal P, Braz RF, Cheng C, Monteiro GR, et al. (2004) An emerging peri-urban pattern of infection with Leishmania chagasi, the protozoan causing visceral leishmaniasis in northeast Brazil. Scand J Infect Dis 36: 443-449. (Pubitemid 39089194)
33. Snider H, Lezama-Davila C, Alexander J, Satoskar AR. (2009) Sex hormones and modulation of immunity against leishmaniasis. Neuroimmunomodulation 16: 106-13.
34. Guerra-Silveira F, Abad-Franch F. (2013) Sex bias in infectious disease epidemiology: patterns and processes. PLoS One. 8(4): e62390. doi: 10.1371/journal.pone.0062390.
35. Sundar S, More DK, Singh MK, Singh VP, Sharma S, et al. (2000) Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin Infect Dis. 31: 1104-7. (Pubitemid 32299375)
36. Das VN, Ranjan A, Bimal S, Siddique NA, Pandey K, et al. (2005) Magnitude of unresponsiveness to sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar. Natl Med J India. 18: 131-3. (Pubitemid 41158105)
37. Shaddy RE, Denne SC; Committee on Drugs and Committee on Pediatric Research (2010) Clinical report-guidelines for the ethical conduct of studies to evaluate drugs in pediatric populations. Pediatrics. 125: 850-60.
38. Jha TK, Sundar S, Thakur CP, Bachmann P, Karbwang J, et al. (1999) Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis. N Engl J Med. 341: 1795-800.
39. Rahman M, Ahmed BN, Faiz MA, Chowdhury MZ, Islam QT, et al. (2011) Phase IV trial of miltefosine in adults and children for treatment of visceral leishmaniasis (kala-azar) in Bangladesh. Am J Trop Med Hyg. 85: 66-9.
40. Bhattacharya SK, Jha TK, Sundar S, Thakur CP, Engel J, et al. (2004) Efficacy and tolerability of miltefosine for childhood visceral leishmaniasis in India. Clin Infect Dis 38: 217-21. (Pubitemid 38113029)
41. Ritmeijer K, Dejenie A, Assefa Y, Hundie TB, Mesure J, et al. (2006) A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection. Clin Infect Dis. 43: 357-64. (Pubitemid 44078909)
42. Singh UK, Prasad R, Kumar R, Jaiswal BP. (2006) Miltefosine in children with visceral leishmaniasis. Indian J Pediatr. 43: 1076-80. (Pubitemid 46021077)